Search Result

Results for "

Progesterone Receptor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Progesterone Receptor (57) 17β-HSD (1) Akt (1) Aldose Reductase (1) Androgen Receptor (9) Apoptosis (3) Autophagy (14) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (8) Estrogen Receptor/ERR (6) FKBP (3) Fluorescent Dye (1) GABA Receptor (1) Glucocorticoid Receptor (15) GnRH Receptor (1) HIV (4) IFNAR (1) Isotope-Labeled Compounds (14) Mineralocorticoid Receptor (7) Neurokinin Receptor (3) NF-κB (1) NO Synthase (5) Oxytocin Receptor (1) p38 MAPK (1) Phosphatase (2) PROTACs (1) Reference Standards (9)
By Research Areas:	Cancer (37) Cardiovascular Disease (9) Endocrinology (56) Inflammation/Immunology (7) Metabolic Disease (3) Neurological Disease (4)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Glucocorticoid receptor agonist 1 Publications Verification	Glucocorticoid Receptor	Metabolic Disease Inflammation/Immunology Endocrinology
Glucocorticoid receptor agonist is a Glucocorticoid receptor agonist that acts on Glucocorticoid receptor (GR), progesterone receptor (PR) and mineralocorticoid receptor (MR) with the IC₅₀ values of 2.1 , 1200 and 210 nM, respectively. Glucocorticoid receptor agonist has steroid-like anti-inflammatory properties and may be used to improve metabolism and reduce increased levels of body fat and serum insulin .

Medroxyprogesterone 5+ Cited Publications 17α-Hydroxy-6α-methylProgesterone; U8840	Progesterone Receptor	Endocrinology Cancer
Medroxyprogesterone (17α-Hydroxy-6α-methylprogesterone) is a synthetic human variant of progesterone that is a progesterone receptor agonist with oral activity. Medroxyprogesterone can induce cell proliferation through the PI3K/Akt signaling pathway. Medroxyprogesterone has an inhibitory effect on atherosclerosis in mice. The progesterone agonist activity of Medroxyprogesterone is less effective than Medroxyprogesterone acetate (HY-B0469) .

Asoprisnil J867	Progesterone Receptor	Endocrinology
Asoprisnil (J867), a selective **progesterone receptor** modulator, exhibits mixed progesterone agonist and antagonist effects on various progesterone targeted tissues in animal and human .

Cymipristone	Progesterone Receptor	Others
Cymipristone (ZXH-951), a **progesterone receptor** antagonist, is used potentially for termination of intrauterine pregnancy .

ZK112993	Progesterone Receptor	Cancer
ZK112993 is a potent progesterone receptor (PR) antagonist. ZK112993 significantly inhibits the growth of T61 human tumors in nude mice .

PR antagonist 1	Progesterone Receptor	Endocrinology
PR antagonist 1 (compound 8) is a selective progesterone receptor (PR) antagonist, and can be used for the research of a variety of progesterone-related diseases and disorders such as endometriosis and uterine fibroids .

RU 45196	Fluorescent Dye	Others
RU 45196 is an 11 beta-substituted 19-norsteroid of the estra-4,9-diene series. RU 45196 displays fluorescence properties (excitation at 480 nm, emission at 525 nm) as well as high binding affinities for the glucocorticoid and progesterone receptors .

Onapristone ZK 98299	Progesterone Receptor	Cancer
Onapristone is a **progesterone receptor antagonist, with K_d*s of 11.6 nM and 11.90 nM for human endometrium and myometrium progesterone* receptor in saturation analysis. Onapristone has antitumor activity .

Norgestomet	Progesterone Receptor	Others
Norgestomet is a compound with progesterone receptor agonist activity. The synthetic product has high purity and agonist activity on the progesterone receptor, while its 17β-isomer is inactive.

Nomegestrol	Progesterone Receptor	Endocrinology Cancer
Nomegestrol is a potent and orally available progestin, acts as a selective full **progesterone receptor agonist, with a K_d** of 5.44 nM for rat uterine progesterone receptor, and has moderate antiandrogenic activity and strong antiestrogenic activity.

Ulipristal CDB-3236; Deacetyl CDB-2914	Progesterone Receptor	Endocrinology Cancer
Ulipristal (CDB 3236) is a selective **progesterone receptor** modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system .

Vilaprisan BAY 1002670	Progesterone Receptor	Cancer
Vilaprisan is a selective progesterone receptor modulator (SPRM), which targets **progesterone receptors. Vilaprisan can inhibit cell proliferation and stimulate apoptosis**. Vilaprisan has oral efficacy and anti-proliferative activity against uterine leiomyoma (UF ).

Demegestone Lutionex	Glucocorticoid Receptor	Endocrinology
Demegestone is an agonist of theprogesterone receptor .

Medroxyprogesterone acetate 25+ Cited Publications MedroxyProgesterone 17-acetate; Farlutin	Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite	Endocrinology Cancer
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

Mifepristone Maximum Cited Publications 52 Publications Verification RU486; RU 38486	Endogenous Metabolite Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

PF-02413873 PF-2413873	Progesterone Receptor	Endocrinology
PF-02413873 (PF-2413873) is a potent selective, fully competitive and orally active nonsteroidal progesterone receptor (PR) antagonist, with a K_i of 2.6 nM. PF-02413873 can block progesterone binding and PR nuclear translocation, and inhibit endometrial growth in vivo .

PF 02367982	Progesterone Receptor	Endocrinology
PF 02367982 is a potent and select progesterone receptor (PR) antagonist with an IC₅₀ value of 47.3 nM. PF 02367982 has oral activity .

Promegestone R-5020; Surgestone	Progesterone Receptor	Endocrinology Cancer
Promegestone (R-5020), a progestin, is a potent progesterone receptor (PR) agonist. Promegestone has the potential for endocrine regulation and cancer research .

AL-438	Glucocorticoid Receptor	Inflammation/Immunology
AL-438 is a potent, selective and orally active glucocorticoid receptor modulator with K_is of 2.5, 1786, 53, 1440, >1000 nM for glucocorticoid receptor, progesterone receptor, mineralocorticoid receptor, androgen receptor, estrogen receptor, respectively. AL-438 shows antiinflammatory activity .

OP-3633	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
OP-3633 is a potent and selective steroidal *glucocorticoid receptor* (GR) antagonist with an IC₅₀** of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism .

Cridanimod 1 Publications Verification	Progesterone Receptor IFNAR	Inflammation/Immunology Cancer
Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer .

Medroxyprogesterone acetate (Standard) 25+ Cited Publications MedroxyProgesterone 17-acetate(Standard); Farlutin (Standard)	Reference Standards Progesterone Receptor Androgen Receptor Glucocorticoid Receptor Endogenous Metabolite	Endocrinology Cancer
Medroxyprogesterone acetate (Standard) is the analytical standard of Medroxyprogesterone acetate. This product is intended for research and analytical applications. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with *progesterone, androgen* and glucocorticoid receptors .

Mifepristone (Standard) Maximum Cited Publications 52 Publications Verification RU486 (Standard); RU 38486 (Standard)	Reference Standards Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (Standard) is the analytical standard of Mifepristone. This product is intended for research and analytical applications. Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

(Rac)-Finerenone (Rac)-BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .

Dexamethasone oxetanone Dex-Ox	Progesterone Receptor	Endocrinology
Dexamethasone oxetanone (Dex-Ox), a derivative of the glucocorticoid-selective steroid Dexamethasone (Dex), is an antiglucocorticoid. Dexamethasone oxetanone is an antiprogestin with significant agonist activity with progesterone receptor (PR) A and B isoforms .

Nestoron 1 Publications Verification ST-1435; Elcometrine	Progesterone Receptor	Endocrinology
Nestoron (ST-1435) is a 19-norprogesterone derivative with high affinity and selectivity for **progesterone receptors**. Nestoron is a highly selective and potent progestogen that can be used as a hormonal contraceptive .

Etonogestrel 3-Oxodesogestrel; 3-keto-Desogestrel	Drug Metabolite Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP	Endocrinology
Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to **progesterone receptors** and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

PF-3882845	Mineralocorticoid Receptor Progesterone Receptor	Cardiovascular Disease Metabolic Disease
PF-3882845 is a remarkably high affinity selective and orally efficacious mineralocorticoid receptor (MR binding IC₅₀=2.7 nM) antagonist for hypertension and nephropathy. PF-3882845 also binds to **progesterone receptor (PR) with the binding IC₅₀** of 310 nM .

PF-998425	Androgen Receptor	Endocrinology
PF-998425 is a potent, selective nonsteroidal *androgen receptor* (AR) antagonist with an IC₅₀** of 37 nM and 43 nM in AR binding and cellular assays, respectively. PF-998425 has low activity on common receptors and enzymes, such as progesterone receptor. PF-998425 can be used for sebum control and androgenetic alopecia research .

Ulipristal acetate 3 Publications Verification CDB-2914	Progesterone Receptor Autophagy	Endocrinology Cancer
Ulipristal acetate (CDB-2914) is an orally active, selective **progesterone receptor** modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

Finerenone 4 Publications Verification BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

ORG 33628	Progesterone Receptor	Endocrinology Cancer
ORG 33628 is a potent and selective **progesterone receptor** modulator. ORG 33628 shows anti-progestational and anti-glucocorticoid activity. ORG 33628 shows ovulation-inhibitory activity. ORG 33628 has the potential for the research of breast and endometrium .

Elinzanetant NT-814; BAY3427080	Neurokinin Receptor	Cardiovascular Disease Neurological Disease
Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

ZK 216348 (+)-ZK 216348	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
ZK 216348 ((+)-ZK 216348) is a nonsteroidal selective glucocorticoid receptor agonist with an IC₅₀ of 20.3 nM. ZK 216348 also binds to Progesterone and mineralocorticoid receptors with IC₅₀s of 20.4 nM and 79.9 nM, respectively. ZK 216348 has antiinflammatory activity similar to Prednisolone and induces less transactivation-mediated side effects .

Etonogestrel (Standard) 3-Oxodesogestrel (Standard); 3-keto-Desogestrel (Standard)	Drug Metabolite Reference Standards Estrogen Receptor/ERR Progesterone Receptor Endogenous Metabolite FKBP	Endocrinology
Etonogestrel (Standard) is the analytical standard of Etonogestrel. This product is intended for research and analytical applications. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

Mifepristone methochloride RU486 methochloride; RU 38486 methochloride	Progesterone Receptor	Endocrinology
Mifepristone (RU486) methochloride is a glucocorticoid antagonist that blocks peripheral glucocorticoid and progesterone receptors. Mifepristone methochloride has been shown to have minimal effects on intraocular pressure in treated rabbits. Mifepristone methochloride was developed as a water-soluble formulation to enhance ocular penetration of the drug.

5β-Dihydroprogesterone 1 Publications Verification 5βDHP	Oxytocin Receptor	Endocrinology
5β-Dihydroprogesterone (5βDHP) is the metabolite of Progesterone (HY-N0437). 5β-Dihydroprogesterone binds to oxytocin receptor, reduces the Oxytocin (HY-17571)-induced calcium signal transduction, thereby exhibiting the tocolytic activity .

Finerenone (Standard) BAY 94-8862 (Standard)	Reference Standards Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Finerenone-d3 BAY 94-8862-d₃	Mineralocorticoid Receptor	Others
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR) antagonist (IC₅₀*=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor* (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

Cat. No.	Product Name

HY-L074

Anti-Breast Cancer Compound Library

2,624 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 2,624 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Cat. No.	Product Name	Chemical Structure

HY-B0469S

Medroxyprogesterone acetate-d3
Medroxyprogesterone acetate-d₃ is deuterium labeled Medroxyprogesterone acetate. Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors .

HY-13683S

Mifepristone-d3
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-B0084S2

Dienogest-d6
Dienogest-d₆ is deuterium labeled Dienogest (HY-B0084). Dienogest is an orally active progesterone receptor agonist that can be used in the study of endometriosis ^.

HY-B0648S

Medroxyprogesterone-d3
Medroxyprogesterone-d₃ is the deuterium labeled Medroxyprogesterone. Medroxyprogesterone is a progestin, a synthetic variant of the human hormone progesterone and a potent progesterone receptor agonist.

HY-14959S

Ulipristal-d3
Ulipristal-d₃ (CDB-3236-d₃) is deuterium labeled Ulipristal. Ulipristal (CDB 3236) is a selective **progesterone receptor** modulator (SPRM). Ulipristal binds to the progesteron receptor, thereby inhibiting PR-mediated gene expression, and interfering with progesterone activity in the reproductive system .

HY-13683S2

Mifepristone-d6
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a **progesterone receptor** (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-B0652S1

Etonogestrel-d6
Etonogestrel-d₆ is deuterium labeled Etonogestrel. Etonogestrel (3-Oxodesogestrel), a biologically active metabolite of progestin Desogestrel, binds with high affinity to progesterone receptors and estrogen receptors in the target organs . Etonogestrel induce FKBP51 mRNA and protein expression in cultured human endometrial stromal cells (HESCs) .

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-16508S

Ulipristal acetate-d6
Ulipristal acetate-d₆ is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective progesterone receptor modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

HY-111372S1

Finerenone-d5

Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-B0251S

Eplerenone-d3
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC₅₀ of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .

HY-13683S1

Mifepristone-13C,d3

Mifepristone- ¹³C,d₃ is the ¹³C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay . Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13676S

Megestrol acetate-d3

Megestrol acetate-d₃ is the deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-13676S1

Megestrol acetate-d3-1

Megestrol acetate-d₃-1 is deuterium labeled Megestrol acetate. Megestrol acetate is a synthetic and orally active progesteronal agent. Megestrol acetate is effective as an appetite stimulant for wasting syndromes such as cachexia. Megestrol acetate decreases nuclear and cytosol androgen receptors human BPH tissue. Megestrol acetate has the potential for HIV study and downregulates autophagic catabolic pathway .

HY-16508S1

Ulipristal acetate-d3
Ulipristal acetate-d₃ (CDB-2914-d₃) is deuterium labeled Ulipristal acetate. Ulipristal acetate (CDB-2914) is an orally active, selective **progesterone receptor** modulator (SPRM). Ulipristal acetate stimulates the autophagic response selectively in leiomyoma cells. Ulipristal acetate has the potential for benign gynecological conditions treatment, such as uterine myoma .

HY-109171S

Elinzanetant-d3
Elinzanetant-d₃ (NT-814-d₃) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women .

HY-106827S1

Trimegestone-13C,d3

Trimegestone- ¹³C,d₃ is ¹³C and deuterated labeled Trimegestone (HY-106827). Trimegestone (RU 27987) is an orally active 19-norpregnane progestin. Trimegestone binds to progesterone receptor (PR) with an IC₅₀ value of 3.3 nM (rat PR). Trimegestone increases alkaline phosphatase activity (EC₅₀=0.1 nM) but not luciferase activity. Trimegestone also shows a weak antiandrogenic activity (weak androgen receptor affinity). Trimegestone can be used in studies of contraception or menopausal syndromes .

HY-B0084S4

Dienogest-13C,15N,d4

Dienogest-13C,15N,d4 (STS 557-13C,15N,d4) is the ¹³C, ¹⁵N and deuterium labeled isotope of Dienogest (HY-B0084). Dienogest (STS-557) is an orally active and selective progesterone receptor agonist that effectively reduces the gene expression of COX-2, mPGES-1 and aromatase. Dienogest also inhibits the mRNA and protein expression of PGE₂ synthase and the activation of NF-κB. Dienogest can be used in studies of endometriosis, menopause and menorrhagia .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82121

	Progesterone Receptor Antibody (YA1866) PGR; NR3C3; Progesterone Receptor; PR; Nuclear Receptor subfamily 3 group C member 3	WB, IHC-P, ICC/IF, IP	Human
	Progesterone Receptor Antibody (YA1866) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1866), targeting Progesterone Receptor, with a predicted molecular weight of 99 kDa (observed band size: 118 kDa). Progesterone Receptor Antibody (YA1866) can be used for WB, IHC-P, ICC/IF, IP experiment in human background.

HY-P83386

	p23 Antibody (YA3131) PTGES3; P23; TEBP; Prostaglandin E synthase 3; Cytosolic prostaglandin E2 synthase; cPGES; Hsp90 co-chaperone; Progesterone Receptor complex p23; Telomerase-binding protein p23	WB, ICC/IF, IP	Human, Mouse, Rat
	p23 Antibody (YA3131) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3131), targeting p23, with a predicted molecular weight of 19 kDa (observed band size: 23 kDa). p23 Antibody (YA3131) can be used for WB, ICC/IF, IP experiment in human, mouse, rat background.

HY-P81991

	*Phospho-Progesterone* Receptor (Ser190) Antibody (YA1736)** PGR; NR3C3; Progesterone Receptor; PR; Nuclear Receptor subfamily 3 group C member 3	WB, IHC-F, IHC-P, ICC/IF, IP	Human
	Phospho-Progesterone Receptor (Ser190) Antibody (YA1736) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1736), targeting Phospho-Progesterone Receptor (Ser190), with a predicted molecular weight of 99 kDa (observed band size: 90/118 kDa). Phospho-Progesterone Receptor (Ser190) Antibody (YA1736) can be used for WB, IHC-F, IHC-P, ICC/IF, IP experiment in human background.

HY-P85965

	PR Antibody (YA5657) Progesterone Receptor; PR; Nuclear Receptor subfamily 3 group C member 3;	IHC-P, WB, ICC/IF, ELISA	Human, Mouse, Rat, Rabbit
	PR Antibody (YA5657) is a mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PR. It can be applicated for IHC-P, WB, ICC/IF, ELISA assays, in the background of human, mouse, rat, rabbit.

HY-P85433

	Hip Antibody (YA5125) ST13; AAG2; FAM10A1; HIP; SNC6; Hsc70-interacting protein; Hip; Aging-associated protein 2; Progesterone Receptor-associated p48 protein; Protein FAM10A1; Putative tumor suppressor ST13; Renal carcinoma antigen NY-REN-33; Suppression of tum	WB, IHC-P, ICC/IF	Human, Bovine, Dog, Pig
	Hip Antibody (YA5125) is a mouse-derived and non-conjugated monoclonal antibody, targeting to Hip. It can be applicated for WB, IHC-P, ICC/IF assays, in the background of human, bovine, dog, pig.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-139659

ARD-61		PROTAC Synthesis
ARD-61 is a highly potent, effective and specific *PROTAC androgen receptor* (AR)** degrader. ARD-61 potently and effectively induces AR and progesterone receptors (PR) degradation in AR+ cancer cell lines. ARD-61 induces apoptosis and effectively induces tumor growth inhibition in the MDA-MB-453 xenograft model in mice . ARD-61 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-111302

Norgestrienone		Alkynes
Norgestrienone is a progestin receptor agonist. Norgestrienone is commonly used as a progesterone compound in birth control pills and can be combined with ethinylestradiol. Norgestrienone is a click chemical. It contains Alkyne groups and can undergo copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with molecules containing Azide groups. Norgestrienone can be used in the study of hereditary angioneurotic edema .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks